Maxcyte (MXCT) Share-based Compensation (2020 - 2026)

Maxcyte (MXCT) has 7 years of Share-based Compensation data on file, last reported at $1.1 million in Q1 2026.

• On a quarterly basis, Share-based Compensation fell 62.45% year-over-year to $1.1 million in Q1 2026; TTM through Mar 2026 was $8.0 million, a 37.11% decrease from a year earlier, with the FY2025 full-year figure at $9.2 million, down 29.58% from the prior year.
• Share-based Compensation for Q1 2026 stood at $1.1 million, up from $706000.0 in the prior quarter.
• Over the last five years, Share-based Compensation for MXCT reached as high as $20.7 million in Q3 2024 and fell as low as -$3.2 million in Q4 2022.
• Historically, Share-based Compensation has averaged $5.2 million across 5 years, with a median of $3.2 million in 2022.
• Across the five-year window, Share-based Compensation tumbled 228.97% in 2022 and jumped 473.54% in 2024, its largest moves.
• Year by year, Share-based Compensation stood at -$3.2 million in 2022, then jumped by 213.18% to $3.6 million in 2023, then declined by 12.31% to $3.1 million in 2024, then plunged by 77.47% to $706000.0 in 2025, then soared by 61.61% to $1.1 million in 2026.
• Per Business Quant data, the three most recent Share-based Compensation figures were $1.1 million in Q1 2026, $706000.0 in Q4 2025, and $14.4 million in Q3 2025.